Evotec to Report First Quarter 2014 Results on 14 May 2014
07 May 2014 - 9:40PM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN: DE0005664809) will report
its financial results for the first quarter of 2014 on Wednesday,
14 May 2014.
The Company is going to hold a conference call to discuss the
results as well as to provide an update on its performance. The
conference will be held in English.
Conference call details
Date: |
Wednesday, 14 May 2014 |
Time: |
09.30 am CEST (08.30 am BST, 3.30 am
EST) |
|
|
|
|
From Germany: |
+49 (0) 69 2017 44 210 |
From UK: |
+44 20 7153 9154 |
From USA: |
+1 877 423 0830 |
Access Code: |
129176# |
A simultaneous slide presentation for participants dialling in
via phone is available at http://www.audio-webcast.com/ password:
evotec0514.
Webcast details
To join the audio webcast and to access the presentation slides
you will find a link on our home page www.evotec.com shortly before
the event.
A replay of the conference call will be available for 24 hours
and can be accessed in Europe by dialling +49 69 2017 44 221
(Germany) or +44 20 3364 5200 (UK) and in the US by dialling +1 855
839 8920. The access code is 350788#. The on-demand version of the
webcast will be available on our website:
http://www.evotec.com/article/en/Investoren/Finanzberichte-2012-2014/238/6.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has
existing development partnerships and product candidates both in
clinical and pre-clinical development. These include partnerships
with Boehringer Ingelheim, MedImmune and Andromeda in the field of
diabetes, with Janssen Pharmaceuticals in the field of depression
and with Roche in the field of Alzheimer's disease. For additional
information please go to www.evotec.com.
FORWARD LOOKING
STATEMENTS— Information set forth in
this press release contains forward-looking statements, which
involve a number of risks and uncertainties. The forward-looking
statements contained herein represent the judgement of Evotec as of
the date of this report. Such forward-looking statements are
neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and
which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024